Zn2+ inhibits nitric oxide formation in response to lipopolysaccharides

Implication in its anti-inflammatory activity

Gamal Abou-Mohamed, Andreas Papapetropoulos, John D. Catravas, Robert William Caldwell

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

There is compelling evidence to indicate an anti-inflammatory action of Zn2+. Most inflammatory diseases are associated with an increase of the inducible form of nitric oxide (NO) synthase. Additionally, inflammatory mediators such as histamine or bradykinin stimulate the constitutive NO synthase. Thus, the present study was undertaken to investigate whether Zn2+ inhibits production of inducible NO synthase and/or constitutive NO synthase activity to produce NO. Lipopolysaccharide, 5 mg/kg i.v., administered to Zn2+-deficient (ZD) rats, rats supplemented with Zn2+ sulfate (ZG), 10 mg/kg s.c., or controls resulted in a significant reduction of their serum Zn2+. The levels of N(G)-nitro-L-arginine methylester (L- NAME)-sensitive cyclic GMP (cGMP) in aortas isolated from ZD or ZG were significantly lower than those obtained from control animals. Zinc (100-150 μM) produced a dose-dependent inhibition of lipopolysaccharide or interleukin-1β-induced NO formation in isolated rat aortic smooth muscle cells. Compared to cyclohexamide or actinomycin-D, the time course of inhibition of NO formation by 150 μM Zn2+ did not suggest an effect of Zn2+ on inducible NO synthase protein synthesis. Moreover, Zn2+ (150 μM) significantly reduced the rate of conversion of [3H]arginine to [3H]citrulline in lung homogenates from lipopolysaccharide-treated rats. Incubation of rat aortic smooth muscle cells and bovine pulmonary artery endothelial cell co-cultures with Zn2+ (150 μM) caused a significant reduction in basal and bradykinin- or A-23187-induced formation of cGMP. Thus, our results indicate that Zn2+ is capable of inhibiting lipopolysaccharide- or interleukin-1β-induced NO formation as well as NO formation by constitutive NO synthase basally or in response to bradykinin or A-23187, and may explain the reported anti-inflammatory activity of Zn2+.

Original languageEnglish (US)
Pages (from-to)265-272
Number of pages8
JournalEuropean Journal of Pharmacology
Volume341
Issue number2-3
DOIs
StatePublished - Jan 12 1998

Fingerprint

Lipopolysaccharides
Nitric Oxide
Anti-Inflammatory Agents
Bradykinin
Nitric Oxide Synthase Type II
Nitric Oxide Synthase
Cyclic GMP
Calcimycin
Interleukin-1
Smooth Muscle Myocytes
Arginine
Citrulline
NG-Nitroarginine Methyl Ester
Dactinomycin
Coculture Techniques
Histamine
Pulmonary Artery
Sulfates
Aorta
Zinc

Keywords

  • Endotoxin
  • Inflammation
  • Lipopolysaccharide
  • Nitric oxide (NO)
  • Nitric oxide (NO) synthase
  • Zn

ASJC Scopus subject areas

  • Pharmacology

Cite this

Zn2+ inhibits nitric oxide formation in response to lipopolysaccharides : Implication in its anti-inflammatory activity. / Abou-Mohamed, Gamal; Papapetropoulos, Andreas; D. Catravas, John; Caldwell, Robert William.

In: European Journal of Pharmacology, Vol. 341, No. 2-3, 12.01.1998, p. 265-272.

Research output: Contribution to journalArticle

@article{9ffb093a2c2045eb9d854536dfc5adde,
title = "Zn2+ inhibits nitric oxide formation in response to lipopolysaccharides: Implication in its anti-inflammatory activity",
abstract = "There is compelling evidence to indicate an anti-inflammatory action of Zn2+. Most inflammatory diseases are associated with an increase of the inducible form of nitric oxide (NO) synthase. Additionally, inflammatory mediators such as histamine or bradykinin stimulate the constitutive NO synthase. Thus, the present study was undertaken to investigate whether Zn2+ inhibits production of inducible NO synthase and/or constitutive NO synthase activity to produce NO. Lipopolysaccharide, 5 mg/kg i.v., administered to Zn2+-deficient (ZD) rats, rats supplemented with Zn2+ sulfate (ZG), 10 mg/kg s.c., or controls resulted in a significant reduction of their serum Zn2+. The levels of N(G)-nitro-L-arginine methylester (L- NAME)-sensitive cyclic GMP (cGMP) in aortas isolated from ZD or ZG were significantly lower than those obtained from control animals. Zinc (100-150 μM) produced a dose-dependent inhibition of lipopolysaccharide or interleukin-1β-induced NO formation in isolated rat aortic smooth muscle cells. Compared to cyclohexamide or actinomycin-D, the time course of inhibition of NO formation by 150 μM Zn2+ did not suggest an effect of Zn2+ on inducible NO synthase protein synthesis. Moreover, Zn2+ (150 μM) significantly reduced the rate of conversion of [3H]arginine to [3H]citrulline in lung homogenates from lipopolysaccharide-treated rats. Incubation of rat aortic smooth muscle cells and bovine pulmonary artery endothelial cell co-cultures with Zn2+ (150 μM) caused a significant reduction in basal and bradykinin- or A-23187-induced formation of cGMP. Thus, our results indicate that Zn2+ is capable of inhibiting lipopolysaccharide- or interleukin-1β-induced NO formation as well as NO formation by constitutive NO synthase basally or in response to bradykinin or A-23187, and may explain the reported anti-inflammatory activity of Zn2+.",
keywords = "Endotoxin, Inflammation, Lipopolysaccharide, Nitric oxide (NO), Nitric oxide (NO) synthase, Zn",
author = "Gamal Abou-Mohamed and Andreas Papapetropoulos and {D. Catravas}, John and Caldwell, {Robert William}",
year = "1998",
month = "1",
day = "12",
doi = "10.1016/S0014-2999(97)01416-7",
language = "English (US)",
volume = "341",
pages = "265--272",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Zn2+ inhibits nitric oxide formation in response to lipopolysaccharides

T2 - Implication in its anti-inflammatory activity

AU - Abou-Mohamed, Gamal

AU - Papapetropoulos, Andreas

AU - D. Catravas, John

AU - Caldwell, Robert William

PY - 1998/1/12

Y1 - 1998/1/12

N2 - There is compelling evidence to indicate an anti-inflammatory action of Zn2+. Most inflammatory diseases are associated with an increase of the inducible form of nitric oxide (NO) synthase. Additionally, inflammatory mediators such as histamine or bradykinin stimulate the constitutive NO synthase. Thus, the present study was undertaken to investigate whether Zn2+ inhibits production of inducible NO synthase and/or constitutive NO synthase activity to produce NO. Lipopolysaccharide, 5 mg/kg i.v., administered to Zn2+-deficient (ZD) rats, rats supplemented with Zn2+ sulfate (ZG), 10 mg/kg s.c., or controls resulted in a significant reduction of their serum Zn2+. The levels of N(G)-nitro-L-arginine methylester (L- NAME)-sensitive cyclic GMP (cGMP) in aortas isolated from ZD or ZG were significantly lower than those obtained from control animals. Zinc (100-150 μM) produced a dose-dependent inhibition of lipopolysaccharide or interleukin-1β-induced NO formation in isolated rat aortic smooth muscle cells. Compared to cyclohexamide or actinomycin-D, the time course of inhibition of NO formation by 150 μM Zn2+ did not suggest an effect of Zn2+ on inducible NO synthase protein synthesis. Moreover, Zn2+ (150 μM) significantly reduced the rate of conversion of [3H]arginine to [3H]citrulline in lung homogenates from lipopolysaccharide-treated rats. Incubation of rat aortic smooth muscle cells and bovine pulmonary artery endothelial cell co-cultures with Zn2+ (150 μM) caused a significant reduction in basal and bradykinin- or A-23187-induced formation of cGMP. Thus, our results indicate that Zn2+ is capable of inhibiting lipopolysaccharide- or interleukin-1β-induced NO formation as well as NO formation by constitutive NO synthase basally or in response to bradykinin or A-23187, and may explain the reported anti-inflammatory activity of Zn2+.

AB - There is compelling evidence to indicate an anti-inflammatory action of Zn2+. Most inflammatory diseases are associated with an increase of the inducible form of nitric oxide (NO) synthase. Additionally, inflammatory mediators such as histamine or bradykinin stimulate the constitutive NO synthase. Thus, the present study was undertaken to investigate whether Zn2+ inhibits production of inducible NO synthase and/or constitutive NO synthase activity to produce NO. Lipopolysaccharide, 5 mg/kg i.v., administered to Zn2+-deficient (ZD) rats, rats supplemented with Zn2+ sulfate (ZG), 10 mg/kg s.c., or controls resulted in a significant reduction of their serum Zn2+. The levels of N(G)-nitro-L-arginine methylester (L- NAME)-sensitive cyclic GMP (cGMP) in aortas isolated from ZD or ZG were significantly lower than those obtained from control animals. Zinc (100-150 μM) produced a dose-dependent inhibition of lipopolysaccharide or interleukin-1β-induced NO formation in isolated rat aortic smooth muscle cells. Compared to cyclohexamide or actinomycin-D, the time course of inhibition of NO formation by 150 μM Zn2+ did not suggest an effect of Zn2+ on inducible NO synthase protein synthesis. Moreover, Zn2+ (150 μM) significantly reduced the rate of conversion of [3H]arginine to [3H]citrulline in lung homogenates from lipopolysaccharide-treated rats. Incubation of rat aortic smooth muscle cells and bovine pulmonary artery endothelial cell co-cultures with Zn2+ (150 μM) caused a significant reduction in basal and bradykinin- or A-23187-induced formation of cGMP. Thus, our results indicate that Zn2+ is capable of inhibiting lipopolysaccharide- or interleukin-1β-induced NO formation as well as NO formation by constitutive NO synthase basally or in response to bradykinin or A-23187, and may explain the reported anti-inflammatory activity of Zn2+.

KW - Endotoxin

KW - Inflammation

KW - Lipopolysaccharide

KW - Nitric oxide (NO)

KW - Nitric oxide (NO) synthase

KW - Zn

UR - http://www.scopus.com/inward/record.url?scp=0032509563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032509563&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(97)01416-7

DO - 10.1016/S0014-2999(97)01416-7

M3 - Article

VL - 341

SP - 265

EP - 272

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -